Quetiapine Fumarate Tablets 25 mg + Quetiapine Fumarate
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasting State
Conditions
Fasting State
Trial Timeline
Apr 1, 2011 → Nov 1, 2011
NCT ID
NCT01603173About Quetiapine Fumarate Tablets 25 mg + Quetiapine Fumarate
Quetiapine Fumarate Tablets 25 mg + Quetiapine Fumarate is a phase 1 stage product being developed by Ipca Laboratories for Fasting State. The current trial status is completed. This product is registered under clinical trial identifier NCT01603173. Target conditions include Fasting State.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01603173 | Phase 1 | Completed |
| NCT01603186 | Phase 1 | Completed |
Competing Products
20 competing products in Fasting State